PhRMA Statement on WTO TRIPS Waiver Negotiations

WASHINGTON, D.C. (March 15, 2022) – Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Megan Van Etten issued the following statement after news reports of developments concerning a proposed WTO TRIPS waiver on intellectual property for COVID-19 vaccines:

“The fact remains that efforts to waive intellectual property commitments are unnecessary and harmful to our collective work to end the pandemic. Strong intellectual property protections, voluntary technology transfers and partnerships are on target to facilitate the production of more than 20 billion doses in 2022 – more than enough to vaccinate the world – without confiscating intellectual property. Global leaders should now focus on the real challenges of distributing and administering vaccines to people around the world.”

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $1.1 trillion in the search for new treatments and cures, including $102.3 billion in 2021 alone. 

Connect with PhRMA

For information on how innovative medicines save lives, please visit: 

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.